Schedule 13G ownership disclosure
GT BIOPHARMA INC
Common Stock · CUSIP: 36254L308
Event date: 2025-05-29
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Bristol Investment Fund, Ltd.
Shares: 74,524.00 · Class: 2.367%
- Bristol Capital, LLC
Shares: 0.00 · Class: 4.76%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001683168-25-004168
- Form type
- SCHEDULE 13G/A
- Filer
- BRISTOL INVESTMENT FUND LTD
- CIK
- CIK 1174866
- Filed
- Jun 02, 2025
- Reporting period
- May 29, 2025
- Description
- Schedule 13G beneficial ownership